THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
https://doi.org/10.15690/vsp.v11i4.374
Abstract
Respiratory syncytial virus plays a significant role in etiology of respiratory infections in infants, and preterm children have much
higher risk of severe course of the disease, than common population of children at the age less than 2 years old. Palivizumab is used
efficiently to prevent this infection. The aim of this study was to assess the efficacy of the costs on palivizumab in preterm children
in the Russian Federation. The assessment was based on meta-analysis of randomized clinical trials. According to the World Health organization recommendations, the acceptable value of the variable «costs/efficacy» must not be higher than threefold of the gross domestic product per person. On the assumption of this fact, the coefficient «costs/efficacy» for the Russian Federation according to the 2011 year results must not be higher than 1140 thousand rubles per 1 extra year of life. Analysis from the position of health care system shows, that coefficient «costs/efficacy» with palivazumab usage in children with gestation age from 28 to 32 weeks ranges
from 594,4 to 1030,4 thousand roubles per 1 extra year of life when starting the prophylaxis during first 6 month of life. Under the social perspective of the study (accounting for direct and indirect costs) the coefficient «costs/efficacy» decreases to 515,8–951,8 thousands roubles per 1 extra year of life. Thereby, nowadays the prophylaxis of severe respiratory cyncytial infection with palivazumab is acceptable according to the economical point of view in preterm children with the gestation age 32 weeks and less when starting during first 6 months of life.
higher risk of severe course of the disease, than common population of children at the age less than 2 years old. Palivizumab is used
efficiently to prevent this infection. The aim of this study was to assess the efficacy of the costs on palivizumab in preterm children
in the Russian Federation. The assessment was based on meta-analysis of randomized clinical trials. According to the World Health organization recommendations, the acceptable value of the variable «costs/efficacy» must not be higher than threefold of the gross domestic product per person. On the assumption of this fact, the coefficient «costs/efficacy» for the Russian Federation according to the 2011 year results must not be higher than 1140 thousand rubles per 1 extra year of life. Analysis from the position of health care system shows, that coefficient «costs/efficacy» with palivazumab usage in children with gestation age from 28 to 32 weeks ranges
from 594,4 to 1030,4 thousand roubles per 1 extra year of life when starting the prophylaxis during first 6 month of life. Under the social perspective of the study (accounting for direct and indirect costs) the coefficient «costs/efficacy» decreases to 515,8–951,8 thousands roubles per 1 extra year of life. Thereby, nowadays the prophylaxis of severe respiratory cyncytial infection with palivazumab is acceptable according to the economical point of view in preterm children with the gestation age 32 weeks and less when starting during first 6 months of life.
About the Authors
A. V. Rudakova
Scientific Research Institute of Children Infections of the Federal Medical-Biological Agency, St. Petersburg
Russian Federation
Alla Rudakova, Doctor of Pharmaceutical Sciences, senior research associate of the department of organization of medical care
Russian Federation
Alla Rudakova, Doctor of Pharmaceutical Sciences, senior research associate of the department of organization of medical care
I. V. Babachenko
Scientific Research Institute of Children Infections of the Federal Medical-Biological Agency, St. Petersburg
Russian Federation
Russian Federation
V. B. Rovnyi
Scientific Research Institute of Children Infections of the Federal Medical-Biological Agency, St. Petersburg
Russian Federation
Russian Federation
A. N. Uskov
Scientific Research Institute of Children Infections of the Federal Medical-Biological Agency, St. Petersburg
Russian Federation
Russian Federation
Yu. V. Lobzin
Scientific Research Institute of Children Infections of the Federal Medical-Biological Agency, St. Petersburg
Russian Federation
Russian Federation
References
1. Joffe S., Escobar G. J., Black S. B. et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999; 104: 894–899.
2. Lacaze-Masmonteil T., Truffert P., Pinquier D. et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch. Dis. Child. 2004; 89: 562–567.
3. Shay D. K., Holman R. C., Newman R. D. et al. Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA. 1999; 282: 1440–1446.
4. Hampp С., Saidi A., Winterstein A. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J. Pediatr. 2010; 156 (6): 953–959.
5. Checchia P., Nalysnyk L., Fernandes A. et al. Mortality and morbidity among high-risk preterm infants receiving palivizumab prophylaxis: a systematic review and meta-analysis. Pediatr. Crit. Care Med. 2011; 12 (5): 580–588.
6. American Academy of Pediatrics. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants (The IMpact-RSV Study Group). Pediatrics. 1998; 102: 531–537.
7. Kusuda S. et al. Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003. Pediatr. Int. 2006; 48: 362–368.
8. Perez Perez G., Navarro Merino M. Perez R. et al. Respiratory morbidity after hospital discharge in premature infants born at < or = 32 weeks gestation with bronchopulmonary dysplasia. Anales de Pediatria. 2004; 60: 117–124.
9. Shrier I., Boivin J.-F., Steele R. et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am. J. Epidemiol. 2007; 166: 1203–1209.
10. Garrison L., Neumann P., Erickson P. et al. Using real-world data for coverage and payment decisions: the ISPOR Real- World Data Task Force report. Value Health. 2007; 10 (5): 326–335.
11. Life tables for WHO Member States. 2009. (www.who.int)
12. Henderson J., Hilliard T. N., Sherriff A. et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr. Allergy Immunol. 2005; 16: 386–392.
13. Дрожжев М. Е. и др. Современные показатели распространенности бронхиальной астмы среди детей. Пульмонология. 2002; 1: 42–46.
14. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 3-е изд., испр. и доп. М.: Атмосфера. 2008. 108.
15. Артюхов И. П., Ильенкова Н. А., Шульмин А. В., Степанова Л. В. Анализ клинико-экономической эффективности регулярного наблюдения врачом-аллергологом детей с бронхиальной астмой. Сибирский медицинский журнал. 2010; 5: 100–102.
16. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2012 г. (www.spboms.ru)
17. Зырянов С. К., Белоусов Ю. Б. Фармакоэкономическая оценка терапии бронхиальной астмы Форадилом Комби. Фарма коэкономика. 2011; 4 (4): 41–49.
18. Доскин В. А., Келлер Х., Мураенко Н. М., Тонкова-Ямпольская Р. В. Морфофункциональные константы детского организма: справочник. М.: Медицина. 1997. 288 с.
19. Дементьева Г. М., Короткова Е. В. Дифференцированная оцен ка детей с низкой массой при рождении. Вопр. охр. мат. и дет. 1981; 2: 15–20.
20. Chiou C. F., Weaver M. R. et al. Development of the multiattribute Pediatric Asthma Health Outcome Measure (PAHOM). Int. J. Qual. Health Care. 2005; 17: 23–30.
21. Hlatky M., Owens D., Sanders G. Cost-effectiveness as an outcome in randomized clinical trials. Clin. Trial.s 2006; 3: 543. DOI: 10.1177/1740774506073105.
22. Rawlins M., Culyer A. National Institute for Clinical Excellence and its value judgments. BMJ. 2004; 329: 224–227.
23. Resch В., Gusenleitnerl W., Nuijten M. et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin. Therapeutics. 2008; 30 (4): 749–760.
24. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization. 2001.
25. Gaziano T. Cardiovascular disease in the developing world and its costeffective management. Cardiology Rounds. 2005; 9 (2): 3547–3553.
Review
For citations:
Rudakova A.V., Babachenko I.V., Rovnyi V.B., Uskov A.N., Lobzin Yu.V. THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS. Current Pediatrics. 2012;11(4):142-147. (In Russ.) https://doi.org/10.15690/vsp.v11i4.374
Views:
842
Email this article 
